Bukwang Pharm Receives 'AA' Grade in Comprehensive ESG Evaluation

Bukwang Pharmaceutical recently announced that it received an AA rating in the '2023 Second Half ESG Comprehensive Evaluation' announced by Sustainvest, a specialized ESG (Environment, Social, Governance) evaluation agency.

Headquarters of Bukwang Pharmaceutical in Dongjak-gu, Seoul [Photo by Bukwang Pharmaceutical]

Sustainvest publishes annual ESG management level evaluation results for about 1,000 listed companies. The evaluation results are utilized by major domestic institutional investors for ESG investments. This evaluation covered a total of 1,270 companies, including 755 listed on the KOSPI market, 310 listed on the KOSDAQ market, and 205 unlisted companies. A size rating classified by asset scale is used.

Bukwang Pharmaceutical received an AA rating, the highest grade in the size category, and an A rating in the overall category in this evaluation. Sustainvest explained in the ESG brief, "Bukwang Pharmaceutical's ESG rating in 2023 is AA, indicating excellent management of ESG risks and opportunities, with an improvement in rating compared to the previous period." ESG analysis evaluates non-financial factors and risks that significantly impact a company's sustainability from an ESG perspective, awarding higher scores to companies whose management activities are environmentally and socially friendly and have sound governance.

To internalize ESG management, Bukwang Pharmaceutical has established an internal ESG organization and has continuously strived to practice and internalize sustainable management, a global trend. In particular, in this Sustainvest ESG comprehensive evaluation, Bukwang Pharmaceutical received excellent scores in the environmental sector for production processes, in the social sector for human resource management, and in governance for shareholders' rights and the composition and activities of the board of directors. Bukwang Pharmaceutical has established and operates the international environmental management standard 'ISO 14001,' and due to these efforts, it has recorded zero violations of environmental regulations over the past three years. Additionally, its achievements in the social and governance sectors were also recognized.

A representative of Bukwang Pharmaceutical stated, "This Sustainvest evaluation is a meaningful result recognizing our capabilities through the expansion of ESG management, even before publishing an official sustainability report," and added, "We will continue to make steady efforts in ESG management and plan to consistently disclose ESG management activities, starting with adding an ESG section through this website renewal."

This content was produced with the assistance of AI translation services.